Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Physostigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 15/20 | 1.00 |
| ▸ | BCHE | P06276 | 12/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.79 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Physostigmine SCHEMBL29787035 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL41555 | 1.00 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Salicylic Acid SCHEMBL8671807 | 0.93 | ACHE (0.87) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL9988368 | 0.89 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL24044 | 0.89 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL4104619 | 0.89 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL13930339 | 0.89 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| (+)-Physostigmine SCHEMBL15677750 | 0.89 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL24045 | 0.89 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 | |
| Physostigmine SCHEMBL29482277 | 0.89 | ACHE (1.00) | ACHEBCHEKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2593 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2024163315-A2 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | DEVORE DALE (US) | 2024-08-08 | — | — | WO | claimed |
| US-20240252446-A1 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | SUSTAINED DRUG DELIVERY LLC | 2024-08-01 | — | — | US | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| CN-117241773-A | Polymer medicine bottle with standard external dimensions and reduced internal volume | SIO2医疗产品有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230330045-A1 | THE ANTIVIRAL DRUG TILORONE IS A POTENT AND SELECTIVE INHIBITOR OF ACETYLCHOLINESTERASE | COLLABORATIONS PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | claimed |
| WO-1992017162-A1 | LYOPHILIZED EMULSION | WARNER-LAMBERT COMPANY (US) | 1992-10-15 | — | — | WO | claimed |
| WO-1992005770-A1 | DRUG DELIVERY VEHICLES SUSPENDED IN NONAQUEOUS PERFLUORINATED CARRIER | ALLERGAN, INC. (US) | 1992-04-16 | — | — | WO | claimed |
| EP-0126684-B1 | DRUG DELIVERY SYSTEM UTILIZING THERMOSETTING GELS | MERCK & CO. INC. (US) | 1991-08-28 | — | — | EP | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| US-4278679-A | ANTIHISTAMINE, PREVENTION OF ANTICHOLINERGIC EFFECT | CHROMALLOY AMERICAN CORPORATION (US) | 1981-07-14 | — | — | US | claimed |
| US-4278667-A | Method of treating tardive dyskinesia by oral dosage form of a physostigmine compound | CHROMALLOY AMERICAN CORPORATION (US) | 1981-07-14 | — | — | US | claimed |
| US-4066747-A | Polymeric orthoesters housing beneficial drug for controlled release therefrom | ALZA CORPORATION (US) | 1978-01-03 | — | — | US | claimed |
| US-4014335-A | Ocular drug delivery device | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-3962414-A | Structured bioerodible drug delivery device | ALZA CORPORATION (US) | 1976-06-08 | — | — | US | claimed |